Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients.

Mauland KK, Ju Z, Tangen IL, Berg A, Kalland KH, Øyan AM, Bjørge L, Westin SN, Krakstad C, Trovik J, Mills GB, Hoivik EA, Johanna Werner HM.

Oncotarget. 2017 Oct 31;8(63):106989-107001. doi: 10.18632/oncotarget.22203. eCollection 2017 Dec 5.

2.

HER2 expression patterns in paired primary and metastatic endometrial cancer lesions.

Halle MK, Tangen IL, Berg HF, Hoivik EA, Mauland KK, Kusonmano K, Berg A, Hurtado A, Kalland KH, Øyan AM, Stefansson I, Vintermyr OK, Werner HM, Haldorsen IS, Trovik J, Salvesen HB, Krakstad C.

Br J Cancer. 2018 Feb 6;118(3):378-387. doi: 10.1038/bjc.2017.422. Epub 2017 Nov 23.

PMID:
29169184
3.

Small molecule promotes β-catenin citrullination and inhibits Wnt signaling in cancer.

Qu Y, Olsen JR, Yuan X, Cheng PF, Levesque MP, Brokstad KA, Hoffman PS, Oyan AM, Zhang W, Kalland KH, Ke X.

Nat Chem Biol. 2018 Jan;14(1):94-101. doi: 10.1038/nchembio.2510. Epub 2017 Oct 30.

PMID:
29083417
4.

PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer.

Mjos S, Werner HMJ, Birkeland E, Holst F, Berg A, Halle MK, Tangen IL, Kusonmano K, Mauland KK, Oyan AM, Kalland KH, Lewis AE, Mills GB, Krakstad C, Trovik J, Salvesen HB, Hoivik EA.

Sci Rep. 2017 Aug 31;7(1):10240. doi: 10.1038/s41598-017-10717-z.

5.

An androgen response element driven reporter assay for the detection of androgen receptor activity in prostate cells.

Azeem W, Hellem MR, Olsen JR, Hua Y, Marvyin K, Qu Y, Lin B, Ke X, Øyan AM, Kalland KH.

PLoS One. 2017 Jun 1;12(6):e0177861. doi: 10.1371/journal.pone.0177861. eCollection 2017.

6.

Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival.

Mauland KK, Wik E, Hoivik EA, Kusonmano K, Halle MK, Berg A, Haugland HK, Øyan AM, Kalland KH, Stefansson IM, Akslen LA, Krakstad C, Trovik J, Werner HM, Salvesen HB.

Oncotarget. 2017 Feb 7;8(6):9696-9707. doi: 10.18632/oncotarget.14201.

7.

Axitinib blocks Wnt/β-catenin signaling and directs asymmetric cell division in cancer.

Qu Y, Gharbi N, Yuan X, Olsen JR, Blicher P, Dalhus B, Brokstad KA, Lin B, Øyan AM, Zhang W, Kalland KH, Ke X.

Proc Natl Acad Sci U S A. 2016 Aug 16;113(33):9339-44. doi: 10.1073/pnas.1604520113. Epub 2016 Aug 1.

8.

Androgen receptor as potential therapeutic target in metastatic endometrial cancer.

Tangen IL, Onyango TB, Kopperud R, Berg A, Halle MK, Øyan AM, Werner HM, Trovik J, Kalland KH, Salvesen HB, Krakstad C.

Oncotarget. 2016 Aug 2;7(31):49289-49298. doi: 10.18632/oncotarget.10334.

9.

Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes.

Olsen JR, Azeem W, Hellem MR, Marvyin K, Hua Y, Qu Y, Li L, Lin B, Ke X, Øyan AM, Kalland K.

BMC Cancer. 2016 Jul 4;16:377. doi: 10.1186/s12885-016-2453-4.

10.

Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses.

Bredholt G, Mannelqvist M, Stefansson IM, Birkeland E, Bø TH, Øyan AM, Trovik J, Kalland KH, Jonassen I, Salvesen HB, Wik E, Akslen LA.

Oncotarget. 2015 Nov 24;6(37):39676-91. doi: 10.18632/oncotarget.5344.

11.

ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma.

Krakstad C, Tangen IL, Hoivik EA, Halle MK, Berg A, Werner HM, Ræder MB, Kusonmano K, Zou JX, Øyan AM, Stefansson I, Trovik J, Kalland KH, Chen HW, Salvesen HB.

Oncotarget. 2015 Sep 29;6(29):28440-52. doi: 10.18632/oncotarget.4955.

12.

Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer.

Stefansson IM, Raeder M, Wik E, Mannelqvist M, Kusonmano K, Knutsvik G, Haldorsen I, Trovik J, Øyan AM, Kalland KH, Staff AC, Salvesen HB, Akslen LA.

Oncotarget. 2015 Apr 30;6(12):10634-45.

13.

Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.

Berg A, Hoivik EA, Mjøs S, Holst F, Werner HM, Tangen IL, Taylor-Weiner A, Gibson WJ, Kusonmano K, Wik E, Trovik J, Halle MK, Øyan AM, Kalland KH, Cherniack AD, Beroukhim R, Stefansson I, Mills GB, Krakstad C, Salvesen HB.

Oncotarget. 2015 Jan 20;6(2):1327-39.

14.

Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations.

Wik E, Trovik J, Kusonmano K, Birkeland E, Raeder MB, Pashtan I, Hoivik EA, Krakstad C, Werner HM, Holst F, Mjøs S, Halle MK, Mannelqvist M, Mauland KK, Oyan AM, Stefansson IM, Petersen K, Simon R, Cherniack AD, Meyerson M, Kalland KH, Akslen LA, Salvesen HB.

Gynecol Oncol. 2014 Sep;134(3):599-606. doi: 10.1016/j.ygyno.2014.06.026. Epub 2014 Jul 1.

PMID:
24995579
15.

High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors.

Engerud H, Tangen IL, Berg A, Kusonmano K, Halle MK, Oyan AM, Kalland KH, Stefansson I, Trovik J, Salvesen HB, Krakstad C.

Br J Cancer. 2014 Jul 8;111(1):78-84. doi: 10.1038/bjc.2014.262. Epub 2014 May 22.

16.

Switch in FOXA1 status associates with endometrial cancer progression.

Tangen IL, Krakstad C, Halle MK, Werner HM, Oyan AM, Kusonmano K, Petersen K, Kalland KH, Akslen LA, Trovik J, Hurtado A, Salvesen HB.

PLoS One. 2014 May 21;9(5):e98069. doi: 10.1371/journal.pone.0098069. eCollection 2014.

17.

Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.

Hoivik EA, Kusonmano K, Halle MK, Berg A, Wik E, Werner HM, Petersen K, Oyan AM, Kalland KH, Krakstad C, Trovik J, Widschwendter M, Salvesen HB.

Oncotarget. 2014 Feb 28;5(4):1052-61.

18.

Spontaneous reversion of the angiogenic phenotype to a nonangiogenic and dormant state in human tumors.

Rogers MS, Novak K, Zurakowski D, Cryan LM, Blois A, Lifshits E, Bø TH, Oyan AM, Bender ER, Lampa M, Kang SY, Naxerova K, Kalland KH, Straume O, Akslen LA, Watnick RS, Folkman J, Naumov GN.

Mol Cancer Res. 2014 May;12(5):754-64. doi: 10.1158/1541-7786.MCR-13-0532-T. Epub 2014 Feb 26.

19.

Generation of prostate tumor-initiating cells is associated with elevation of reactive oxygen species and IL-6/STAT3 signaling.

Qu Y, Oyan AM, Liu R, Hua Y, Zhang J, Hovland R, Popa M, Liu X, Brokstad KA, Simon R, Molven A, Lin B, Zhang WD, McCormack E, Kalland KH, Ke XS.

Cancer Res. 2013 Dec 1;73(23):7090-100. doi: 10.1158/0008-5472.CAN-13-1560. Epub 2013 Oct 7.

20.

Differences in proliferative capacity of primary human acute myelogenous leukaemia cells are associated with altered gene expression profiles and can be used for subclassification of patients.

Reikvam H, Øyan AM, Kalland KH, Hovland R, Hatfield KJ, Bruserud Ø.

Cell Prolif. 2013 Oct;46(5):554-62. doi: 10.1111/cpr.12057.

PMID:
24073609
21.

p63 attenuates epithelial to mesenchymal potential in an experimental prostate cell model.

Olsen JR, Oyan AM, Rostad K, Hellem MR, Liu J, Li L, Micklem DR, Haugen H, Lorens JB, Rotter V, Ke XS, Lin B, Kalland KH.

PLoS One. 2013 May 1;8(5):e62547. doi: 10.1371/journal.pone.0062547. Print 2013.

22.

High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition.

Wik E, Birkeland E, Trovik J, Werner HM, Hoivik EA, Mjos S, Krakstad C, Kusonmano K, Mauland K, Stefansson IM, Holst F, Petersen K, Oyan AM, Simon R, Kalland KH, Ricketts W, Akslen LA, Salvesen HB.

Clin Cancer Res. 2013 May 1;19(9):2331-41. doi: 10.1158/1078-0432.CCR-12-3413. Epub 2013 Mar 28.

23.

Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers.

Raeder MB, Birkeland E, Trovik J, Krakstad C, Shehata S, Schumacher S, Zack TI, Krohn A, Werner HM, Moody SE, Wik E, Stefansson IM, Holst F, Oyan AM, Tamayo P, Mesirov JP, Kalland KH, Akslen LA, Simon R, Beroukhim R, Salvesen HB.

PLoS One. 2013;8(2):e54873. doi: 10.1371/journal.pone.0054873. Epub 2013 Feb 5.

24.

MiR-182 and miR-203 induce mesenchymal to epithelial transition and self-sufficiency of growth signals via repressing SNAI2 in prostate cells.

Qu Y, Li WC, Hellem MR, Rostad K, Popa M, McCormack E, Oyan AM, Kalland KH, Ke XS.

Int J Cancer. 2013 Aug 1;133(3):544-55. doi: 10.1002/ijc.28056. Epub 2013 Feb 27.

25.

Lack of estrogen receptor-α is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma.

Wik E, Ræder MB, Krakstad C, Trovik J, Birkeland E, Hoivik EA, Mjos S, Werner HM, Mannelqvist M, Stefansson IM, Oyan AM, Kalland KH, Akslen LA, Salvesen HB.

Clin Cancer Res. 2013 Mar 1;19(5):1094-105. doi: 10.1158/1078-0432.CCR-12-3039. Epub 2013 Jan 14.

26.

High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated.

Krakstad C, Birkeland E, Seidel D, Kusonmano K, Petersen K, Mjøs S, Hoivik EA, Wik E, Halle MK, Øyan AM, Kalland KH, Werner HM, Trovik J, Salvesen H.

PLoS One. 2012;7(12):e52795. doi: 10.1371/journal.pone.0052795. Epub 2012 Dec 27.

27.

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.

Birkeland E, Wik E, Mjøs S, Hoivik EA, Trovik J, Werner HM, Kusonmano K, Petersen K, Raeder MB, Holst F, Øyan AM, Kalland KH, Akslen LA, Simon R, Krakstad C, Salvesen HB.

Br J Cancer. 2012 Dec 4;107(12):1997-2004. doi: 10.1038/bjc.2012.477. Epub 2012 Oct 25.

28.

ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas.

Werner HM, Berg A, Wik E, Birkeland E, Krakstad C, Kusonmano K, Petersen K, Kalland KH, Oyan AM, Akslen LA, Trovik J, Salvesen HB.

Mod Pathol. 2013 Mar;26(3):428-34. doi: 10.1038/modpathol.2012.174. Epub 2012 Oct 19.

29.

Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer.

Straume O, Shimamura T, Lampa MJ, Carretero J, Øyan AM, Jia D, Borgman CL, Soucheray M, Downing SR, Short SM, Kang SY, Wang S, Chen L, Collett K, Bachmann I, Wong KK, Shapiro GI, Kalland KH, Folkman J, Watnick RS, Akslen LA, Naumov GN.

Proc Natl Acad Sci U S A. 2012 May 29;109(22):8699-704. doi: 10.1073/pnas.1017909109. Epub 2012 May 15.

30.

Lipocalin 2 expression is associated with aggressive features of endometrial cancer.

Mannelqvist M, Stefansson IM, Wik E, Kusonmano K, Raeder MB, Øyan AM, Kalland KH, Moses MA, Salvesen HB, Akslen LA.

BMC Cancer. 2012 May 6;12:169. doi: 10.1186/1471-2407-12-169.

31.

Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome.

Krakstad C, Trovik J, Wik E, Engelsen IB, Werner HM, Birkeland E, Raeder MB, Øyan AM, Stefansson IM, Kalland KH, Akslen LA, Salvesen HB.

Br J Cancer. 2012 May 8;106(10):1682-8. doi: 10.1038/bjc.2012.91. Epub 2012 Mar 13.

32.

Gene expression in tumor cells and stroma in dsRed 4T1 tumors in eGFP-expressing mice with and without enhanced oxygenation.

Moen I, Jevne C, Wang J, Kalland KH, Chekenya M, Akslen LA, Sleire L, Enger PØ, Reed RK, Øyan AM, Stuhr LE.

BMC Cancer. 2012 Jan 17;12:21. doi: 10.1186/1471-2407-12-21.

33.

High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer.

Mauland KK, Trovik J, Wik E, Raeder MB, Njølstad TS, Stefansson IM, Oyan AM, Kalland KH, Bjørge T, Akslen LA, Salvesen HB.

Br J Cancer. 2011 Mar 15;104(6):921-6. doi: 10.1038/bjc.2011.46. Epub 2011 Feb 22.

34.

Amplification of the 20q chromosomal arm occurs early in tumorigenic transformation and may initiate cancer.

Tabach Y, Kogan-Sakin I, Buganim Y, Solomon H, Goldfinger N, Hovland R, Ke XS, Oyan AM, Kalland KH, Rotter V, Domany E.

PLoS One. 2011 Jan 31;6(1):e14632. doi: 10.1371/journal.pone.0014632.

35.

Gene expression patterns related to vascular invasion and aggressive features in endometrial cancer.

Mannelqvist M, Stefansson IM, Bredholt G, Hellem Bø T, Oyan AM, Jonassen I, Kalland KH, Salvesen HB, Akslen LA.

Am J Pathol. 2011 Feb;178(2):861-71. doi: 10.1016/j.ajpath.2010.10.040.

36.

Global profiling of histone and DNA methylation reveals epigenetic-based regulation of gene expression during epithelial to mesenchymal transition in prostate cells.

Ke XS, Qu Y, Cheng Y, Li WC, Rotter V, Øyan AM, Kalland KH.

BMC Genomics. 2010 Nov 25;11:669. doi: 10.1186/1471-2164-11-669.

37.

Reprogramming of cell junction modules during stepwise epithelial to mesenchymal transition and accumulation of malignant features in vitro in a prostate cell model.

Ke XS, Li WC, Hovland R, Qu Y, Liu RH, McCormack E, Thorsen F, Olsen JR, Molven A, Kogan-Sakin I, Rotter V, Akslen LA, Oyan AM, Kalland KH.

Exp Cell Res. 2011 Jan 15;317(2):234-47. doi: 10.1016/j.yexcr.2010.10.009. Epub 2010 Oct 20.

PMID:
20969863
38.

Stathmin is superior to AKT and phospho-AKT staining for the detection of phosphoinositide 3-kinase activation and aggressive endometrial cancer.

Trovik J, Wik E, Stefansson I, Carter SL, Beroukhim R, Oyan AM, Kalland KH, Akslen LA, Salvesen HB.

Histopathology. 2010 Oct;57(4):641-6. doi: 10.1111/j.1365-2559.2010.03661.x. No abstract available.

PMID:
20955391
39.

Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation.

Reikvam H, Hatfield KJ, Oyan AM, Kalland KH, Kittang AO, Bruserud O.

Eur J Haematol. 2010 Mar;84(3):239-51. doi: 10.1111/j.1600-0609.2009.01382.x. Epub 2009 Nov 17.

PMID:
19922462
40.

TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis.

Rostad K, Hellwinkel OJ, Haukaas SA, Halvorsen OJ, Øyan AM, Haese A, Budäus L, Albrecht H, Akslen LA, Schlomm T, Kalland KH.

APMIS. 2009 Aug;117(8):575-82. doi: 10.1111/j.1600-0463.2009.02517.x.

PMID:
19664128
41.

Hyperoxic treatment induces mesenchymal-to-epithelial transition in a rat adenocarcinoma model.

Moen I, Øyan AM, Kalland KH, Tronstad KJ, Akslen LA, Chekenya M, Sakariassen PØ, Reed RK, Stuhr LE.

PLoS One. 2009 Jul 28;4(7):e6381. doi: 10.1371/journal.pone.0006381.

42.

Highly infiltrative brain tumours show reduced chemosensitivity associated with a stem cell-like phenotype.

Johannessen TC, Wang J, Skaftnesmo KO, Sakariassen PØ, Enger PØ, Petersen K, Øyan AM, Kalland KH, Bjerkvig R, Tysnes BB.

Neuropathol Appl Neurobiol. 2009 Aug;35(4):380-93. doi: 10.1111/j.1365-2990.2008.01008.x.

PMID:
19508445
43.

Tumour virology--history, status and future challenges.

Kalland KH, Ke XS, Øyan AM.

APMIS. 2009 May;117(5-6):382-99. doi: 10.1111/j.1600-0463.2009.02452.x. Review.

PMID:
19400863
44.

Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia.

Øyan AM, Anensen N, Bø TH, Stordrange L, Jonassen I, Bruserud Ø, Kalland KH, Gjertsen BT.

BMC Cancer. 2009 Mar 5;9:77. doi: 10.1186/1471-2407-9-77.

45.

Genome-wide profiling of histone h3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis.

Ke XS, Qu Y, Rostad K, Li WC, Lin B, Halvorsen OJ, Haukaas SA, Jonassen I, Petersen K, Goldfinger N, Rotter V, Akslen LA, Oyan AM, Kalland KH.

PLoS One. 2009;4(3):e4687. doi: 10.1371/journal.pone.0004687. Epub 2009 Mar 5.

46.

Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation.

Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM, Raeder MB, Sos ML, Engelsen IB, Trovik J, Wik E, Greulich H, Bø TH, Jonassen I, Thomas RK, Zander T, Garraway LA, Oyan AM, Sellers WR, Kalland KH, Meyerson M, Akslen LA, Beroukhim R.

Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4834-9. doi: 10.1073/pnas.0806514106. Epub 2009 Mar 4.

47.

Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators.

Hatfield K, Øyan AM, Ersvaer E, Kalland KH, Lassalle P, Gjertsen BT, Bruserud Ø.

Br J Haematol. 2009 Jan;144(1):53-68. doi: 10.1111/j.1365-2141.2008.07411.x. Epub 2008 Oct 30.

PMID:
19016730
48.

Epithelial to mesenchymal transition of a primary prostate cell line with switches of cell adhesion modules but without malignant transformation.

Ke XS, Qu Y, Goldfinger N, Rostad K, Hovland R, Akslen LA, Rotter V, Øyan AM, Kalland KH.

PLoS One. 2008;3(10):e3368. doi: 10.1371/journal.pone.0003368. Epub 2008 Oct 13.

49.

Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma.

Engelsen IB, Mannelqvist M, Stefansson IM, Carter SL, Beroukhim R, Øyan AM, Otte AP, Kalland KH, Akslen LA, Salvesen HB.

Br J Cancer. 2008 May 20;98(10):1662-9. doi: 10.1038/sj.bjc.6604360. Epub 2008 May 13.

50.

Global gene expression in classification, pathogenetic understanding and identification of therapeutic targets in acute myeloid leukemia.

Oyan AM, Bø TH, Jonassen I, Ulvestad E, Tore Gjertsen B, Bruserud O, Kalland KH.

Curr Pharm Biotechnol. 2007 Dec;8(6):344-54. Review.

PMID:
18289043

Supplemental Content

Support Center